Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Merck (NYSE:MRK) is set to reveal its earnings on Tuesday, July 29, 2025. Historically, MRK stock has exhibited a trend of negative one-day returns following earnings announcements.

Why Merck (MRK) is a Top Value Stock for the Long-Term August 07, 2025 — 09:40 am EDT Written by Zacks Equity Research for Zacks -> ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ratings.

MRK Quantitative Stock Analysis - Peter Lynch July 15, 2025 — 09:04 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for MERCK & CO INC (MRK).

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...